Aviado · Research
Longevity Daily
Thursday, June 11, 2026
Listen
Today's Brief
Today's issue is anchored by a genuine landmark: the first FDA-approved human trial of epigenetic reprogramming therapy has begun, with Life Biosciences dosing its first patient with a drug designed to reset aging at the cellular level. On a more urgent note for supplement users, a new study finds glucosamine may accelerate Alzheimer's progression in people with early cognitive decline — a 25% higher risk worth knowing. Elsewhere, GLP-1 drugs are showing surprising antidepressant effects mediated by the gut microbiome, and Harvard puts a precise number on the optimal strength-training dose for longevity. Creatine, metformin, and the future of fecal transplants round out a packed edition.
10 stories5 peer-reviewed1 trials
Cognitive Health & Neuroprotection
GLP-1 Drugs Cut Depression Symptoms by Reshaping the Gut Microbiome
The GLP-1 agonist liraglutide doesn't just regulate blood sugar and body weight -- it also reduces depressive symptoms by fostering gut bacteria that calm the stress response. Researchers identified a novel microbial pathway through which the drug boosts stress-calming microbes in the gut, which then signal back to the brain. For the millions now taking GLP-1 drugs like semaglutide, these findings suggest mental health benefits may come alongside metabolic ones -- though replication in larger human trials is needed.
Read more →Glucosamine May Accelerate Alzheimer's Progression in People with Early Cognitive Decline
People with mild cognitive impairment who took glucosamine supplements were 25% more likely to progress to Alzheimer's disease than non-users, according to a study published June 9. The finding is backed by mouse model experiments showing that blocking the enzyme that produces glucosamine-like sugars actually improved dementia symptoms -- suggesting a mechanistic link, not just a statistical association. If you're taking glucosamine for joint pain and have any history of cognitive concerns, this warrants a serious conversation with your doctor before continuing.
Read more →Supplements & Compounds
Metformin's Longevity Case Gets Stronger: Connecting Gut Health, Inflammation, and Healthspan
A new synthesis in Psychiatric Times connects the dots between metformin's known mechanisms -- mimicking caloric restriction, modulating the gut microbiome, and suppressing chronic inflammation -- to explain why this diabetes drug has become a serious healthspan candidate. Preclinical data show metformin activates autophagy and reduces inflammatory markers through microbiome pathways that parallel what we see with prolonged fasting. For those tracking the TAME trial's progress, this mechanistic overview makes a compelling scientific case for why the hypothesis deserves its place in longevity research.
Read more →Creatine Is Reinventing Itself as a Brain and Longevity Supplement
Long known for building muscle, creatine is earning serious new attention for brain energy metabolism, cellular resilience, and preserving muscle mass in people taking GLP-1 drugs -- a genuinely novel use case. Manufacturers are now developing clinically supported formats specifically aimed at these aging and cognitive applications, moving the ingredient beyond its gym-focused origins. For health optimizers already using creatine for performance, the longevity and cognitive angles give you more reasons to stay consistent; for those who've avoided it, the evidence base is meaningfully broadening.
Read more →Research & Papers
Epigenetic Clocks Show Adults with Structural Heart Defects Age Up to 5.5 Years Faster Biologically
Adults with moderate or complex congenital heart disease show biological ages up to 5.5 years older than their chronological age, according to a study of 240 participants using multiple epigenetic clocks including PhenoAge, GrimAge2, and DunedinPACE. Critically, patients with simple defects showed no such acceleration -- indicating that structural disease severity, not diagnosis alone, drives the aging differential. For the broader longevity community, the study reinforces the practical utility of epigenetic clocks as tools that can detect systemic vulnerability well before clinical complications emerge.
Read more →A Gut Bacteria Strain Sends Signals That Protect the Lungs from Age-Related Scarring
Research published in Aging Cell has identified a specific Lactobacillus gut bacteria strain that secretes chemical signals entering the bloodstream and measurably decreasing fibrosis in the lungs. The finding extends gut-lung axis research into age-related disease prevention -- fibrosis is a major contributor to declining lung function in older adults. While still pre-clinical, this adds to the growing case that maintaining a Lactobacillus-rich microbiome may carry systemic protective effects that go well beyond digestion.
Read more →Lifestyle & Nutrition
Scientists Are Engineering Artificial Gut Microbiomes to Replace Fecal Transplants
Researchers are moving toward synthetic, standardized gut microbiomes that could deliver the benefits of fecal microbiota transplantation (FMT) -- which consistently produces health improvements in animal aging studies -- without the regulatory obstacles that currently block broad FMT access in the US. Animal data show that transplanting a young donor's microbiome into an older recipient produces measurable benefits, but FDA rules have severely restricted access outside of C. difficile treatment. An engineered microbiome product could eventually make this intervention widely reproducible and available -- a frontier worth watching closely.
Read more →Industry & Policy
World First: The Epigenetic Reprogramming Therapy Designed to Reverse Cellular Aging Has Entered Human Testing
Life Biosciences has dosed the first patient in a Phase 1 trial of ER-100, an epigenetic reprogramming therapy that aims to reset the chemical "age marks" accumulating on DNA -- potentially reversing cellular aging rather than merely slowing it. The trial, FDA-approved in January 2026, targets glaucoma via eye injection, chosen as a contained and measurable starting point before any broader systemic application is attempted. This is the first time partial cellular reprogramming has entered a human body under clinical conditions, making it a genuine inflection point in longevity medicine regardless of how the early results unfold. Safety data will take months to emerge, and the leap from a single-patient eye trial to whole-body anti-aging remains enormous -- but the science has now crossed from theory into the clinic.
Read more →FDA Admits It Can't Keep Up with Rogue Supplement Makers -- Here's What That Means for You
An FDA official speaking at the Council for Responsible Nutrition's virtual conference acknowledged that the agency faces significant structural obstacles to enforcing dietary supplement regulations under DSHEA, the 1994 law governing the category. The gap between what the law permits and what the FDA can realistically police leaves consumers regularly exposed to non-compliant or mislabeled products. For supplement buyers, this is a timely reminder that third-party testing certifications -- NSF, USP, and Informed Sport -- remain the most reliable proxy for product quality until regulatory enforcement catches up.
Read more →